MedPath

Boehringer Ingelheim USA Corporation

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Safety, Tolerability and Efficacy of Micardis® in Patients With Essential Hypertension

Completed
Conditions
Hypertension
Interventions
First Posted Date
2014-06-27
Last Posted Date
2014-07-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
19870
Registration Number
NCT02176850

Inhaled Bronchodilator Association and Quality of Life in Patients With Chronic Obstructive Pulmonary Disease

Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Drug: inhaled bronchodilator
First Posted Date
2014-06-27
Last Posted Date
2014-07-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
2639
Registration Number
NCT02176564

Telmisartan With or Without Hydrochlorothiazide in Patients With Mild-to-moderate Hypertension

Phase 3
Completed
Conditions
Hypertension
Interventions
Drug: Telmisartan/Hydrochlorothiazide
Drug: Placebo
First Posted Date
2014-06-27
Last Posted Date
2014-07-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
491
Registration Number
NCT02177435

BIBR 277 Capsule in Patients With Essential Hypertension

Phase 3
Completed
Conditions
Hypertension
Interventions
Drug: BIBR277 low dose
Drug: BIBR277 medium dose
Drug: BIBR277 high dose
Drug: Placebo matching BIBR277
First Posted Date
2014-06-27
Last Posted Date
2014-07-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
225
Registration Number
NCT02177448

Telmisartan/Hydrochlorothiazide (HCTZ) Fixed Dose Combination Compared to Its Monocomponents in Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BIBR 277 SE and HCTZ
Drug: BIBR 277 SE
First Posted Date
2014-06-27
Last Posted Date
2014-07-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
20
Registration Number
NCT02176512

Effect on Fenoterol Metered Dose Inhaler on the Beta-receptor Population on Lymphocytes in Patients With Bronchial Asthma

Phase 3
Terminated
Conditions
Asthma
Interventions
Drug: DSCG MDI
First Posted Date
2014-06-27
Last Posted Date
2014-07-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
19
Registration Number
NCT02177370

Safety and Efficacy of Two Different Doses of Ipratropium Bromide Versus ATROVENT® Inhalation Aerosol in Adults With Chronic Obstructive Pulmonary Disease

Phase 3
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Drug: Placebo
Drug: Low dose of Ipratropium bromide
Drug: High dose of Ipratropium bromide
First Posted Date
2014-06-27
Last Posted Date
2014-07-17
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
646
Registration Number
NCT02177344

Berodual® Respimat® vs Metered Dose Inhaler in Patients With Chronic Obstructive Pulmonary Disease

Phase 3
Terminated
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Drug: Berodual® Respimat® inhaler
Drug: Berodual® metered dose inhaler
First Posted Date
2014-06-27
Last Posted Date
2014-07-14
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
3
Registration Number
NCT02176187

Relative Bioavailability of BI 691751 Administered With and Without Food to Healthy Male Subjects

Phase 1
Withdrawn
Conditions
Healthy
Interventions
Drug: BI 691751 fasted
Drug: BI 691751 after high fat breakfast
First Posted Date
2014-06-26
Last Posted Date
2014-07-24
Lead Sponsor
Boehringer Ingelheim
Registration Number
NCT02175238
Locations
🇺🇸

1334.28.01001 Boehringer Ingelheim Investigational Site, Madison, Wisconsin, United States

Effect of Multiple BI 1356 Doses of on the Multiple-dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Healthy Female Premenopausal Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Microgynon®
First Posted Date
2014-06-26
Last Posted Date
2014-07-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
18
Registration Number
NCT02175394
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy